Doubts about DOT: Antiretroviral therapy for resource-poor countries

AIDS

Volumn 17, Issue 9, 2003, Pages 1383-1387

  Liechty, Cheryl A ^a   Bangsberg, David R ^a,b  

^a San Francisco General Hospital   (Uganda)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Adherence; Africa; Directly observed therapy; HIV antiretroviral therapy; Resistance; Resource poor

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

AFRICA; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SHORT COURSE THERAPY; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIRECTLY OBSERVED THERAPY; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HUMANS; PATIENT COMPLIANCE; PATIENT RIGHTS; POVERTY; RESOURCE ALLOCATION; TUBERCULOSIS;

EID: 0037999039     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00013     Document Type: Article

References (61)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS; 2000.
2. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001, 358:410-414.
3. Laurence J. The cost effectiveness of antiretroviral therapy for HIV disease. N Engl J Med 2001, 345:68; discussion 68-69.
4. Little SJ, Routy P, Daar ES, Markowitz M, Collier AC, Kop RA, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 756].
5. Popp D, Fisher JD. First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS 2002, 16:676-678.
6. Harvard University. Consensus Statement on Antiretroviral Treatment for AIDS in Poor Countries. Boston: Harvard University; 2001.
7. Farmer P, Learndre F, Mukherjee J, Gupta R, Tarter L. Kim J. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). World Health Bull 2001, 79:1145-1151.
8. Mbewu A. Antiretroviral therapy is only part of it. World Health Bull 2001, 79:1152.
9. United Nations. Blueprint for Action. Africa Recovery 2001, 15:11.
10. James J. Malawi plan to control AIDS Epidemic: Interview with David Scondras. AIDS Treatment News 2001, 371.
11. Salaniponi F. Using lessons learned in the control of tuberculosis to design a structured framework for providing antiretroviral therapy in Malawi. Adv Studies Med 2001, 1:480-482.
12. Bayer R, Dubler NN, Landesman S. The dual epidemics of tuberculosis and AIDS: ethical and policy issues in screening and treatment. Am J Public Health 1993, 83:649-654.
13. WHO. Treatment of Tuberculosis. Guidelines for National Programmes. Geneva: WHO, 1997.
14. Zhang LX, Tu DH, Enarson DA. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000, 4:904-910.
15. Squire S, Wilkinson D. Strengthening DOTS through community care for tuberculosis. BMJ 1997, 315:1395-1396.
16. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment [see comments]. BMJ 1997, 315:1403-1406.
17. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995, 333:229-233.
18. Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998, 352:1340-1343.
19. Kamolratanakul P, Sawert H, Lertmaharit S, Kasetjaroen Y, Akksilp S, Tulaporn C, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999, 93:552-557.
20. Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001, 357:664-669.
21. Khan M, Walley J, Witter S, Imran A, Safdar N. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Health Policy Plan 2002, 17:178-186.
22. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000, 355:1345-1350.
23. Fischl M, Rodriguez A, Scerpella E, Mondroig R, Thompson L, Rechtine D. Impact of directly observed therapy on outcomes in HIV clinical trials. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 71].
24. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002, 34:984-990.
25. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001, 358:404-409.
26. Hader S, Weidle P, Cergnul I, Hanson D, Berkman A, Filmore H, et al. Directly Observed Antiretroviral Therapy (DART) in Residential Treatment Facilities in New York City. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 476].
27. Donnelly J. Prevention urged in AIDS fight; Natsiohs says funds should spend less on HIV treatment. Boston Globe, June 7, 2001.
28. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy treatment outcomes in south Africa. 2003, AIDS. 17:1375-1381.
29. Laurent C, Diakhate N, Gueye NFN, Touré MA, Sow PS; Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18 month follow-up study. AIDS 2002, 16:1363-1370.
30. Sanne I, Ive P, Mcintyre J, Gray G, Mohpapi L, Wood R. Successful antiretroviral therapy in clinical research in South Africa. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 321].
31. Kasper T, Hilderbrand H, Tshabane N, et al. Antiretroviral therapy in primary health care centers in a South African township. XIV International Conference on AIDS. Barcelona, July 2002 [abstract MoOrB1095].
32. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
33. Paterson DL, Swindells S, Mohr J, Brester M, Squier C, Wagener MM, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
34. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001, 33:700-705.
35. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001, 33:1417-1423.
36. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001, 134:968-977.
37. Bangsberg DR, Hecht FM, Charlebois ED, Hays RD, Beck CK, Sanandaji S, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14:357-366.
38. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001, 15:2109-2117.
39. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999, 3:457-465.
40. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis 1999, 3:1-3.
41. Wainberg MA, Friedland G. Public health implications of anti-retroviral therapy and HIV drug resistance [see comments]. JAMA 1998, 279:1977-1983.
42. Altice FL, Friedland GH. The era of adherence to HIV therapy [editorial]. Ann Intern Med 1998, 129:503-505.
43. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA 1996, 276:1955-1956.
44. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B; Wainberg MA, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study [see comments]. JAMA 1998, 279:930-937.
45. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002, 30:278-287.
46. Howard A, Arnsten J, Gardner L, et al. Lack of multi-drug resistance in nonresponders to antiretroviral therapy with poor adherence. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 604].
47. Gallego O, de Mendoza C, Perez-Elias MJ, Guardiola JM, Pedreira J, Dalmau D, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001, 15:1701-1706.
48. Kuritzkes D, Ickovics J, Bassett R, Hellman N, Johnson V. HIV-1 drug resistance and medication adherence in patients receiving NRTIs. HIV Resistance and Pathogenesis Meeting. Scottsdale, June 2001. [abstract 84]
49. Bangsberg D, Charlebois E, Grant R, Holodniy M, Perry S, Nugent Conroy K, et al. Low levels of adherence do not increase risk of HIV drug resistance. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, AIDS, in press.
50. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
51. Stenzel M, McKenzie M, Adelson-Mitty J, Flanigan T. Modified directly observed therapy (MDOT) to enhance adherence to highly active antlretroviral therapy (HAART): 12 month follow-up. XIII International Conference on AIDS. Durban, July 2000 [abstract ThPeb4992].
52. Bangsberg DR, Kagay CR, Porco T, Grant R, Holodniy M, Charlebois ED, et al. Modeling the relationship between adherence and accumulation of protease inhibitor drug resistance mutations based on objectively measured adherence and empirically derived relationships. XIth HIV Drug Resistance Workshop. Seville July 2002 [abstract 160].
53. Kagay C, Porco T, Moss AR, Bangsberg DR. Modified directly observed therapy and adherence case managment improve HIV clinical outcomes but fail to prevent drug resistance. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 2002.
54. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group [see comments]. N Engl J Med 2000, 342:921-929.
55. Hurtig AK, Porter JD, Ogden JA. Tuberculosis control and directly observed therapy from the public health/human rights perspective. Int J Tuberc Lung Dis 1999, 3:553-560.
56. Enzama R, Mbuga F, Turyatemba C. Strategies for delivery of ARVs. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July, 2001 [abstract 327].
57. Whetten-Goldstein K, Nguyen TQ, Sugarman J. So much for keeping secrets: the importance of considering patients' perspectives on maintaining confidentiality. AIDS Care 2001, 13:457-465.
58. Fiscus S, Cohen M. Impact of antiretroviral therapy on the transmission of HIV. National HIV Prevention Conference. Atlanta August, 2001.
59. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS2002, 16:1051-1058.
60. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001, 15:1181-1183.
61. deOlalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla J. Impact of adherence on highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Def Syndr 2001, 30:105-110.